INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Results

20,929 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$60K
3,369 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

Page 369 of 524
← PrevNext →
19
DA
Dignan AndyPresident
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL
$87K
4,924 sh
Mar 4, 2026
Mar 6, 2026
traded Mar 4, 2026
+2d
SEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$70K
340 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$127K
612 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$94K
460 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$239K
1,142 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

18
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$61K
300 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

17
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$300K
1,457 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

16
LM
Lee Bryan MChief Financial Officer
FIVNFive9, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
1,756 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

16
David J. TaylorRSelf
PHParker-Hannifin Corp
Sale
SELL$1,001 – $15KFeb 26, 2026Mar 6, 2026
traded Feb 26, 2026
+8dHouse PTR

Evidence

16
David J. TaylorRSelf
PHParker-Hannifin Corp
Sale
SELL$1,001 – $15KFeb 26, 2026Mar 6, 2026
traded Feb 26, 2026
+8dHouse PTR

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$866K
4,029 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
200 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$19K
93 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$411K
1,883 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
207 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

15
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$389K
1,848 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$152K
743 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$136K
668 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$192K
950 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$140K
698 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$139K
699 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

14
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$141K
697 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

13
CC
Collier CharlesPresident, Roku Media
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$172K
1,715 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

11
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$356K
1,685 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

11
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$11K
53 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

11
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$264K
1,235 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$60K
1,664 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$176K
4,994 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

9
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$185K
5,260 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$126K
570 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$64K
300 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$452K
2,158 sh
Mar 6, 2026Mar 6, 2026
traded Mar 6, 2026
+0dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$73K
350 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$151K
700 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$130K
600 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$110K
500 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence

8
MA
Mitchell AndreaDirector
DAVEDave Inc./DE
Open-market sale · 10b5-1 plan
SELL$67K
300 sh
Mar 5, 2026Mar 6, 2026
traded Mar 5, 2026
+1dSEC Form 4

Evidence